Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
Over the past nine years, we have hosted over 325 leading scientific presentations at the Gibco virtual stem cell event–now 5 Days of Stem Cells. Below is a complete list of presentations and speakers since 2013 with select presentations available*.
If you'd like to share your latest discoveries at this renowned virtual stem cell conference, contact the event coordinator at 5daysofstemcells@thermofisher.com.
Presentation | Speaker | Affiliation |
---|---|---|
Rapid dissociation of 3D spheroids using the Rotea Counterflow Centrifugation System | Michael Akenhead | Thermo Fisher Scientific |
Utilizing the Gibco™ CTS™ Rotea™ System, a versatile closed manufacturing system, for cell and gene therapy development | Emily Benz | ViaCyte |
A fateful decision | Laurie Boyer | Massachusetts Institute of Technology |
Development of humanized mouse models for biomedical research | Michael Brehm | University of Massachusetts Medical School |
Beyond stem cells therapies: Mitochondria as a new living drug in regenerative medicine | Andrés Caicedo | Universidad San Francisco de Quito |
Maturation strategies for iPSC cardiac 3D tissues and phenotypic correction of calmodulinopathy disease models using CRISPRi | Huang Chen-Yu | National Cheng Kung University |
Stem cell-based approaches to study neurological disorders | Derek Dykxhoorn | University of Miami Miller School of Medicine |
Using iPS-derived cells to produce functional human liver organoids | Ernesto Goulart | University of São Paulo |
Adipose-derived stem cells as a cell source for cultivated meat production | Petra Hanga | University College London |
Artificial cells: From therapy to regeneration | Mahdi Hasani | University of California Los Angeles |
Human induced pluripotent stem cells: Applications in neurodevelopmental and neurodegenerative diseases | Youssef Hibaoui | University Hospital of Fribourg |
De-risking preclinical drug development: simultaneous assessment of efficacy and toxicity | James Keck** | The Jackson Laboratory |
Characterizing stems cells using Invitrogen antibodies | Jamuna KS | Thermo Fisher Scientific |
Understanding and modifying cellular age-stage | Christian Nefzger** | University Queensland |
Cell and gene therapies | Jan Nolta** | University of California Davis Health |
Accelerating the future of stem cell research with connected automation | Sean Peschisolido & Sarah Yesford | Thermo Fisher Scientific |
The growing concern of off-target effects: How to measure and minimize off-target effects in your genome editing experiments | Pandhita Pochanard | Thermo Fisher Scientific |
Simplified online tools for CRISPR-Cas9 gene editing design and confirmation | Matt Poling | Thermo Fisher Scientific |
In vitro characterization of mesenchymal stromal cells: Promising uses in spinal cord injury | Carolina Quintero Gil | Bioxcellerator |
Challenges & hurdles for clinical application of iPSC in South Korea | Yeri Alice Rim | Catholic iPSC Research Center (CiRC) |
Placental susceptibility to SARS-CoV-2 and its physiological impact on mesenchymal stem cells | Mairim Solis | Sistema Nacional de Investigación de Panamá |
Advanced stem cell therapies for patients with kidney disease | Cathelijne van den Berg | Leiden University Medical Center |
The importance of quality control assays for pluripotent stem cell line banks | Erik Willems | Thermo Fisher Scientific |
Stem cells and genomics for precision cardiovascular medicine | Joseph Wu** | Stanford Cardiovascular Institute |
Forming hearts and repairing hearts with hPSCs | Robert Zweigerdt** | Hannover Medical School |
**Keynote presenter |
Presentation | Speaker | Affiliation |
---|---|---|
Utilization of stem cells to crack motor neuron development and degeneration | Jun-An Chen** | Institute of Molecular Biology Academia Sinica |
Organoid technology—from adult stem cells to miniature organs | Helmuth Gehart** | Hubrecht Institute for Developmental Biology and Stem Cell Research |
Mammalian DNA methylation landscapes and human cancers | Alexander Meissner** | Max Planck Institute for Molecular Genetics |
Human pluripotent stem cells in understanding genetic cardiovascular disease and effects of drugs | Christine Mummery** | Leiden University Medical Center |
On the road to realizing tissue engineering’s transformative potential: multidisciplinary approach to accelerate bench-to-clinic transition | Nina Tandon and Ben Shepherd** | EpiBone Organovo |
Eliminating inherent genome editing bottlenecks in iPSCs to build physiologically relevant disease models | Erik Willems** | Thermo Fisher Scientific |
Gibco sera—driving quality and innovation in a dynamic market | Matthew Dallas and Chris Scanlon** | Thermo Fisher Scientific |
Industry uses of human pluripotent stem cells | Stuart Chambers | Amgen |
Custom-tailored cardiomyocytes: Directed differentiation of human pluripotent stem cells into defined atrial and ventricular cardiomyocyte subtypes | Lukas Cyganek | University of Göttingen |
Comparison of the teratoma assay and in vitro surrogate tests for assessment of pluripotency of human pluripotent stem cells | Christian Freund | Leiden University Medical Center |
Directed differentiation of hematopoietic cells from human pluripotent stem cells | Alessandra Giorgetti | Center for Regenerative Medicine in Barcelona |
Examining the negative impacts of bioflavonoids on the DNA damage response and DNA repair mechanisms in mouse embryonic stem cells | Donna Goodenow | University of North Carolina at Charlotte |
Mechanisms for assembling and resolving naïve pluripotency | Jacob Hanna | Weizmann Institute of Science |
Pluripotent stem cell bioprocessing platforms for cell therapy manufacturing | Jahid Hasan | Cell and Gene Therapy Catapult |
Identification of a high titer lentiviral production alternative to facilitate regenerative medicine therapies | Calley Hirsch | CCRM |
Building inner ear organoids from human pluripotent stem cells through directed self-assembly | Karl Koehler | Indiana University School of Medicine |
Integrated processes for derivation, expansion and differentiation of hiPSC to blood in IPS-Spheres™ cultures | Alan Lam | Bioprocessing Technology Institute (BTI) of Singapore |
New monoclonal antibodies to defined cell surface proteins on human pluripotent stem cells | Andrew Laslett | Commonwealth Industrial and Scientific Research Organisation or CSIRO |
Genomic profiling reveals novel PAX7 targets CD54, integrin α9β1 and SDC2, as markers for isolation of human ES/iPS cell-derived muscle progenitors | Alessandro Magli | University of Minnesota |
Pluripotent stem cells to explore mechanisms and treatments of neuromuscular diseases | Cécile Martinat | I-Stem French Stem Cell Society |
iPSC-derived neural cells for drug discovery of mitochondrial brain diseases | Alessandro Prigione | Max Delbrueck Center for Molecular Medicine (MDC) |
New insights about Zika virus infection using iPS cells | Stevens Rehen | D'Or Institute for Research and Education (IDOR) & Institute of Biomedical Sciences, Federal University of Rio de Janeiro |
Pancreatic progenitors: from the organ to the plate | Meritxell Rovira | Center for Regenerative Medicine in Barcelona |
Braingineering’s human midbrain organoids as novel model for neurodegenerative diseases | Jens Christian Schwamborn | Braingineering Technologies SARL |
Patient-specific hiPSCs for understanding diabetes disease mechanisms | Adrian Kee Keong Teo | IMCB, A*STAR SBS and LKC Medicine, NUS Medicine |
Preparing for what’s next – keys to a successful career search | Sarah Gibson | Thermo Fisher Scientific |
How to do an elevator pitch that will win you friends, admirers and maybe even funding | Kevin McCormack | California Institute for Regenerative Medicine |
Journal publishing tools that make your research stand out | Rebecca Shumbata | Mary Ann Liebert, Inc. Publishers |
How to get the most out of LinkedIn | Ania Wronski | Thermo Fisher Scientific |
Physiological oxygen: historical and molecular perspective for stem cell culture | Mary Kay Bates | Thermo Fisher Scientific |
New viral and non-viral platforms for T-cell engineering | Xavier de Mollerat du Jeu | Thermo Fisher Scientific |
New Gibco B-27 Plus Neuronal Culture System—next generation media for superior neuronal survival and functionality | Navjot Kaur | Thermo Fisher Scientific |
New tools for improved CRISPR gene-editing in stem cells | James Kehler | Thermo Fisher Scientific |
Highly efficient stem cell engineering via Cas9 protein transfection | Xiquan Liang | Thermo Fisher Scientific |
Comprehensive characterization of pluripotent stem cells | Suman Pradhan | Thermo Fisher Scientific |
**Keynote presenter |
Presentation | Speaker | Affiliation |
---|---|---|
Genetic variability of ps-iPSC and related blood and fibroblasts—somatic mutations | Silke Rickert-Sperling** | Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine Charité - Universitätsmedizin Berlin |
Molecular elucidation and engineering of stem cell fate decisions | David Schaffer** | University of California, Berkeley |
Using patient-derived iPSCs to model and treat inherited retinal degenerative blindness | Budd Tucker** | University of Iowa Carver College of Medicine |
Optimization of your PSCs workflow | Jing He | Thermo Fisher Scientific |
Initiatives to advance stem cell science and medicine at California’s $3 billion stem cell agency | Stephen Lin | California Institute for Regenerative Medicine |
Partnering to advance regenerative medicine and cellular therapies | Morrie Ruffin Michael Werner | Adjuvant Partners Holland & Knight |
Evolving your media system for modern stem cell applications | Rhonda Newman | Thermo Fisher Scientific |
From bench to BLA—a review of common regulatory questions | Joyce Frey-Vasconcells Michael Mendicino Kelli Tanzella | Frey-Vasconcells Consulting, LLC Hybrid Concepts International Thermo Fisher Scientific |
Precise generation of desired human cell-types from embryonic stem cells | Lay Teng Ang | Genome Institute of Singapore |
Derivation of a spectrum of regional motor neuron phenotypes for hindbrain and spinal cord regenerative medicine | Randolph Ashton | University of Wisconsin Madison |
Directed differentiation of induced pluripotent stem cells to hepatic stellate cells | Pau Sancho Bru | Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS) |
Elucidating the physiological function of cellular PrPC using human iPS cell | Vijay Chandrasekar | Universitat Zurich |
‘HipSci' and the ‘Stem cell hotel’: innovative platforms for collaborative phenotyping | Davide Danovi | King's College London |
Disease modelling in pluripotent stem cell-derived cardiomyocytes | Chris Denning | University of Nottingham |
Human pluripotent stem cells for the study of enteric neuropathies | Faranak Fattahi | Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine |
Transitioning to the clinic from proof of concept research: Challenges associated with converting research materials and methods to a clinical grade product. | Ben Fryer | University of Washington School of Medicine |
Human PSC-based disease modeling to study X-linked dystonia-parkinsonism | William Hendriks | Harvard Medical School |
Use of stem cell models to assess genetic change underlying neurodevelopmental disorders | Lachlan Jolly | The University of Adelaide |
Building embryonic lineages | Leo Kurian | CECAD - Cluster of Excellence, Institute for Neurophysiology & Center for Molecular Medicine (CMMC), University of Cologne |
Human umbilical cord mesenchymal cells and the treatment of bronchopulmonary dysplasia | Willie Lin | Meridigen Biotech Co., Ltd. |
Stem cells for regeneration and rescue | Jeanne Loring | The Scripps Research Institute |
First allogeneic mesenchymal stromal cell product approved in India for Buerger’s disease—an unmet medical need | Anish Sen Majumdar | Stempeutics Research |
Transplanted human stem cell-derived interneuron precursors mitigate mouse bladder dysfunction and central neuropathic pain after spinal cord injury | Cory Nicholas | Neurona Therapeutics University of California, San Francisco |
Exploring new avenues for cataract treatment using human pluripotent stem cells | Michael O’Connor | Western Sydney University University of Sydney, |
Challenge toward clinical trial for spinal cord injury using iPS cell | Hideyuki Okano | Keio University School of Medicine Brain Science Institute RIKEN |
Optimizing retinal cell differentiation of human pluripotent stem cells for large-scale disease modeling. | Alice Pébay | University of Melbourne |
From urine to the study of metabolic disease—A patient-driven strategy to decipher PCSK9 roles and functions | Karim Si-Tayeb | l’institut du thorax INSERM |
From millions to billions to trillions – translating your cell discovery into a cell product | Nick Timmins | CCRM, Canada |
Regulation of autologous cell clinical interventions | Bernie Tuch | NSW Stem Cell Network |
Immunomodulation and immunogenicity of human MSC-like cells: What did we learn from in vitro and in vivo studies? | Hans-Dieter Volk | Charité-Universitätsmedizin Berlin |
Translating pluripotent stem cell therapies for focal brain disorders | Dustin Wakeman | RxGen, Inc. |
Improved differentiation of human pluripotent stem cell-derived neurons through reduction of progenitor proliferation: impact on downstream applications | David Kuninger | Thermo Fisher Scientific |
Analyzing stem cell populations using flow cytometry | Jolene Bradford | Thermo Fisher Scientific |
Techniques and recommendations for colony selection and passage of iPSC | Chad MacArthur | Thermo Fisher Scientific |
The matrix equation—solving for the best PSC culture goals | Rhonda Newman | Thermo Fisher Scientific |
iPSC generation and validation: Ensuring the best materials for downstream applications | Rene Quintanilla | Thermo Fisher Scientific |
Delivery solutions for robust CRISPR-based genomic editing in stem cells for disease model generation | Nektaria Andronikou | Thermo Fisher Scientific |
**Keynote presenter |
Presentation | Speaker | Affiliation |
---|---|---|
Genome editing and stem cell engineering for disease modeling | Jon Chesnut** | Thermo Fisher Scientific |
Probing disease mechanisms in ALS and ion-channel epilepsy using iPSCs, reprogramming and optogenetic approaches | Evangelos Kiskinis** | Northwestern University |
Biomaterials for assembly of stem cell-derived human tissues | William Murphy** | University of Wisconsin |
Epigenetic regulation in stem cells and reprogramming | Alexander Meissner | Harvard University Harvard Stem Cell Institute |
Standardizing stem cell research | Alexander Meisner Ernest Wolvetang Tennielle Ludwig | |
Differentiation of midbrain floor plate progenitors and dopaminergic neurons from human pluripotent stem cells | Soojung Shin | Thermo Fisher Scientific |
Essential 8 Flex: Eliminating daily feeding in feeder-free, xeno-free PSC culture system | Matthew Dallas | Thermo Fisher Scientific |
Antibodies for stem cell research | Kara Machledit | Thermo Fisher Scientific |
Highly efficient genome editing and cell engineering in stem cells using CRISPR/Cas9 | Namritha Ravinder Shantanu Kumar | Thermo Fisher Scientific |
Improved T cell function and in vivo engraftment of CAR-T cells expanded ex vivo with CTS Immune Cell SR | Angel Varela Rohena | Thermo Fisher Scientific |
Pluripotent stem cell characterization methods | Deborah Tieberg | Thermo Fisher Scientific |
Pluripotent stem cell culture systems: Identification of appropriate medium, matrix and passaging reagent | Rhonda Newman | Thermo Fisher Scientific |
PSCs to cardiomyocytes in three steps | Alex Hannay | Thermo Fisher Scientific |
Thermo Fisher Scientific’s cell therapy capabilities | Brian Newsom | Thermo Fisher Scientific |
Optimizing retinal cell differentiation of human pluripotent stem cells for large-scale disease modeling | Alice Pébay | University of Melbourne |
HOXA gene expression defines definitive fetal hematopoietic cells differentiated from human embryonic stem cells | Andrew Elefanty | Murdoch Children’s Research Institute |
Muscle stem cells harboring basal levels of pluripotency genes are amenable to pluripotent conversion without using reprogramming factors or small molecules | Bipasha Bose | Yenepoya University |
The use of modified mRNA to enhance the generation of induced neural precursor cells from adult human fibroblasts | Bronwen Connor | University of Auckland |
Functional dissection of disease-associated chromosomal deletions with human iPSCs | Eirini Papapetrou | Icahn School of Medicine at Mount Sinai |
Human oocyte as source of information to study cell pluripotency and reprogramming | Elena González Muñoz | Centro Andaluz de Nanomedicina y Biotecnología (BIONAND) |
Standardized generation of patient-specific iPSC lines and scalable production of PSC-derived cardiomyocytes | Emily Titus | CCRM, Canada |
In vitro quantification of the terminal differentiation potential of pluripotent stem cells | Ernst Wolvetang | University of Queensland |
A novel PSC-based myogenic platform to explore treatment strategies for muscle diseases | Jérôme Chal | Harvard Medical School |
The laminin protein family—key to stem cell culture | Jesper Ericsson | BioLamina |
Variability of cardiomyocyte differentiation among human pluripotent stem cells: A practical screening approach | Katherine Santostefano | University of Florida Center for Cellular Reprogramming |
Modeling predisposition to schizophrenia using hiPSCs | Kristen Brennad | Icahn School of Medicine at Mount Sinai |
Dental pulp of the third molar: a new source of pluripotent-like stem cells | Maher Atari | Universitat Internacional de Catalunya |
Generation of induced pluripotent stem (iPS) cell-derived cardiomyocytes for disease modeling and drug discovery | Nirupama Pike | Stem Cell Theranostics |
Efficient generation of footprint-free patient-specific iPS cells and the application for drug screening | Noemi Fusaki | Keio University School of Medicine |
Scalable xeno-free culture system for human induced pluripotent stem cells | Tiago Fernandes | Institute for Bioengineering and Biosciences |
Tissue engineering of hiPSC for endothelial cell regeneration and cardiac repair | Ye Lei | National Heart Centre Singapore |
Toward large-scale functional genomic studies through the automation of induced pluripotent stem cell derivation, expansion and differentiation | Daniel Paull | New York Stem Cell Foundation |
Modeling eye diseases using human adult retinal pigment epithelium stem cells | Timothy Blenkinsop | Icahn School of Medicine at Mount Sinai |
Combined stem cell transplantation and gene therapy on the regeneration of corticospinal axons after spinal cord injury | Stuart Hodgetts | University of Western Australia |
**Keynote presenter |
Presentation | Speaker | Affiliation |
---|---|---|
The future of pluripotent stem cell banking | Jonathan Loh Yuin-Han | A*STAR Institute of Molecular and Cell Biology |
Utility of gene expression signatures for the characterization of cellular identity | Alexander Meissner | Harvard Stem Cell Institute |
Reprogramming cells to study mental disorders | Stevens Rehen | Institute of Biomedical Sciences, Federal University of Rio de Janeiro and D’Or Institute for Research and Education |
Molecular engineering of biomaterial platforms for scalable stem cell manufacturing | David Schaffer | University of California at Berkeley |
Using iPS cell technology to model human neurodegenerative diseases | Angel Raya | Center for Regenerative Medicine in Barcelona (CMRB) |
Pluripotent stem cells to model human brain development | Chris Fasano | Neural Stem Cell Institute |
Scalable production of human stem/progenitor cells in bioreactor systems | Claudia Lobato da Silva | Stem Cell Bioengineering and Regenerative Medicine Laboratory, Instituto Superior Técnico, Universidade de Lisboa |
Deriving functional hepatocytes from pluripotent stem cells | David Hay | MRC Centre for Regenerative Medicine |
Hematopoietic disease modeling using iPSCs | Deborah French | The Children's Hospital of Philadelphia |
Development of chemically defined cell culture for human pluripotent stem cells | Guokai Chen | University of Macau, China |
Culture adaptation of pluripotent stem cells: an in vitro model for oncogenesis | Ivana Barbaric | University of Sheffield |
iPSCs for modeling disease in Africa | Janine Scholefield | CSIR Biosciences |
Reversibility of the cellular aging physiology through an iPSC state : a new paradigm for human cell rejuvenation | Jean-Marc Lemaitre | Institute of Regenerative Medicine and Biotherapies, INSERM, Stem Cell Core Facility SAFE-iPSC |
Derivation and function of clinical-grade human ESCs in Parkinson's disease monkey models | Jie Hao | Chinese Academy of Sciences |
Knock-in gene correction in pyruvate kinase deficiency patient–derived iPSC, the most common metabolic erythroid disease | Jose Carlos Segovia | CIEMAT/CIBERER |
Developing autologous cell therapy for macular degeneration using IPS cell–derived RPE tissue: a model for public-private partnership | Kapil Bharti | National Eye Institute, National Institutes of Health |
Reprogramming somatic cells using the Sendai virus technology | Laurence Daheron | Harvard Stem Cell Institute |
Mechanisms of reprogramming: applying lessons from mouse models to improve the efficiency of an iPSC core facility | Laurent David | Medical School of University of Nantes |
Induced pluripotent stem cells: time for standards | Mathilde Girard | I-Stem |
Pluripotency factors and cell lineage specification | Michael Puceat | French National Institute of Health and Medical Research, INSERM |
The challenges and possible solutions for transferring cell therapy from the bench to the industry, while assuring high quality and manufacturing efficiency | Ohad Karnieli | Pluristem Therapeutics Inc |
SCL/TAL1-mediated transcriptional network enhances megakaryocytic specification of human embryonic stem cells | Pedro Real | GENYO Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government |
Cellular immune therapy for virus-associated human malignancies and post-transplant infectious complications | Rajiv Khanna | QIMR Centre for Immunotherapy and Vaccine Development QIMR Berghofer Medical Research Institute |
Developing a human embryonic stem cell based therapy for multiple sclerosis | Ren-He Xu | University of Macau |
Developing a human ES cell derived dopamine neuron source for cell therapy in Parkinson's disease—from academic to translational research | Stefan Irion | MSKCC |
Chromatin modifiers in reprogramming | Tamer Onder | Koç University |
iPSC reprogramming from human blood using Sendai virus mediated gene transfer | Wenli Yang | University of Pennsylvania |
Use of pluripotent stem cells to model premature aging syndromes | Xavier Nissan | CECS, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic diseases |
Transcriptome profiling and stem cell-based therapies | Yi Sun | UCLA Institute for Stem Cell Biology and Medicine |
Stage-specific grafting of hESC-derived midbrain dopamine neurons | Yosif Ganat | MSKCC |
Pharmacological modulation of cell fates | Yu Wang | Chinese Academy of Sciences |
Personalized disease model in dish - Starting with Parkinson’s Disease | Jing He Bo Peng | Thermo Fisher Scientific |
Hands-free stem cell research: services to save you time | Carolyn Pettersson | Thermo Fisher Scientific |
Cell therapy logistics—beyond the basics | Dan O’Donnell | Thermo Fisher Scientific |
Trends and considerations for cell therapy development | Eric Roos | Thermo Fisher Scientific |
Considerations for creating a disease model for Parkinson's disease using stem cells | Kurt Vogel | Thermo Fisher Scientific |
Efficient cell specific differentiation systems for iPSC | Mohan Vemuri | Thermo Fisher Scientific |
Antibody based tools and protocols for characterization of pluripotent stem cells | Nirupama Pike | Thermo Fisher Scientific |
Considerations for the culture of pluripotent stem cells | Jennifer Crean | Thermo Fisher Scientific |
Differentiate pluripotent stem cells to contracting cardiomyocytes in 3 easy steps | Alex Hannay | Thermo Fisher Scientific |
Eliminate serum to gain control of your T cell research | Sandra Kuligowski | Thermo Fisher Scientific |
Rapid induction of neural stem cells without the need for EB formation | Alex Hannay | Thermo Fisher Scientific |
Score! A gene expression profile for your iPS lines | Deborah Tieberg | Thermo Fisher Scientific |
Presentation | Speaker | Affiliation |
---|---|---|
Genome editing to generate human cellular disease models | Chad Cowan** | Harvard University |
Pluripotency and differentiation | Alexander Meissner** | Harvard University |
Reprogramming human hematopoietic cells for regenerative medicine | Elias Zambidis** | Johns Hopkins University School of Medicine |
Human pluripotent stem cell-derived dopaminergic neurons for screening | Xianmin Zeng | Buck Institute for Research and Aging; Xcell Science, Inc. |
Transcriptional analysis during reprogramming at the single cell level. | Jose Polo** | Monash University |
Hematopoietic differentiation of human pluripotent stem cells | Junfeng Ji | Zhejiang University |
iPSC-dervied NSCs from Life Technologies Gibco Neural Induction Medium | Michael Edel** | Universitat de Barcelona |
Using iPS cell technology to model human neurodegenerative diseases | Angel Raya** | IBEC, Barcelona |
iPSCs for modeling disease in Africa | Janine Scholefield** | Councel for Scientific and Industrial Research (CSIR) |
Parkinson’s Part I: Life Technologies and the Parkinson’s Institute collaborate to understand the molecular basis for Parkinson’s disease | Roland Leathers | Thermo Fisher Scientific |
Parkinson’s Part II: Generation of induced pluripotent stem cells from Parkinson’s disease fibroblasts | Connie Lebakken | Thermo Fisher Scientific |
Parkinson’s Part III: Generation and characterization of neural stem cells from Parkinson’s disease donor-derived iPSCs | Kun Bi | Thermo Fisher Scientific |
Parkinson’s Part IV: Genome Editing of Parkinson’s Disease iPSCs Using GeneArtPrecision TAL Technology | Spencer Hermanson | Thermo Fisher Scientific |
Considerations for culturing neural stem cells | Yiping Ya, Soojung Shin | Thermo Fisher Scientific |
Considerations for culturing mesenchymal stem cells | Shayne Boucher | Thermo Fisher Scientific |
Considerations for culturing pluripotent stem cells | Marian Piekarczyk | Thermo Fisher Scientific |
Considerations for reprogramming pluripotent stem cells | Chad MacArthur | Thermo Fisher Scientific |
Considerations for characterizing pluripotent stem cells | Rene Quintanilla | Thermo Fisher Scientific |
CytoTune-iPS Sendai 2.0 Reprogramming Kit | Jennifer Crean | Thermo Fisher Scientific |
TaqMan hPSC Scorecard Panel and data analysis software | Deborah Tieberg | Thermo Fisher Scientific |
Essential 8 media and vitronectin | James Lovgren | Thermo Fisher Scientific |
Cell Model Services for stem cell research | Carolyn Pettersson | Thermo Fisher Scientific |
Products and services for neural differentiation | Alex Hannay | Thermo Fisher Scientific |
Genome editing tools—GeneArt TALs & CRISPRs | Farzad Haerizadeh | Thermo Fisher Scientific |
**Keynote presenter |
For Research Use Only. Not for use in diagnostic procedures.